An RNA molecule contributes to therapy resistance of triple negative breast cancer
Smyca promotes the repair of damaged DNA by working closely with FOXM1.
The study uncovers a novel long noncoding RNA, Smyca, that drives DNA repair and immune evasion in triple‑negative breast cancer (TNBC), thereby conferring resistance to chemotherapy and PARP inhibitors. Targeting Smyca with antisense RNA not only impairs DNA repair but also activates immune pathways (cGAS‑STING), turning “immune‑cold” TNBC tumors into “immune‑hot” ones that respond better to combined therapy. This dual action offers a promising strategy to overcome therapy resistance in a subtype of breast cancer with limited targeted options.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC